Jones Cecilia 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Agios (AGIO) CFO Cecilia Jones Receives 3,000 Performance Units
What Happened
Cecilia Jones, CFO of Agios Pharmaceuticals (AGIO), had 3,000 performance stock units (PSUs) converted/exercised and was credited with a grant of 3,000 derivative units on June 18, 2026. Both entries show a $0.00 exercise/acquisition price, so there was no cash paid or received and no immediate marketable shares issued.
Key Details
- Transaction date: June 18, 2026; Form 4 filed June 23, 2026.
- Transaction codes: M = exercise/conversion of a derivative (3,000 units), A = grant/acquisition of a derivative (3,000 units).
- Price/value: $0.00 per unit; total reported value $0.
- Shares owned after transaction: Not disclosed in the filing.
- Notable footnotes:
- F1: Each PSU = contingent right to one common share.
- F2: PSUs were granted March 1, 2025; the specified research milestone was determined met on June 18, 2026; shares related to that milestone will vest on December 31, 2027, subject to continued service.
- F3: Each restricted stock unit (RSU) = contingent right to one common share.
- Filing timeliness: The Form 4 was filed five days after the transaction (June 23 vs. June 18). Form 4s are generally due within two business days, so this filing appears later than the typical deadline.
Context
These were derivative awards tied to achieving a research milestone, not open-market purchases or sales. No cash changed hands and the underlying shares are contingent and will vest on 12/31/2027 if Jones remains employed — so this does not represent immediate insider buying power or a sale.
Insider Transaction Report
- Exercise/Conversion
Performance share units
[F1][F2]2026-06-18−3,000→ 9,000 total→ Common stock (3,000 underlying) - Award
Restricted stock units
[F3][F2]2026-06-18+3,000→ 3,000 total→ Common stock (3,000 underlying)
Footnotes (3)
- [F1]Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F2]Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.
- [F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.